Literature DB >> 12047439

Fluticasone inhibits the progression of allergen-induced structural airway changes.

N J Vanacker1, E Palmans, R A Pauwels, J C Kips.   

Abstract

BACKGROUND: Inhaled corticosteroids are widely used as first-line therapy in patients with asthma. The concept of early introduction is more and more accepted.
OBJECTIVE: In our rat model of airway remodelling, we investigated whether treatment with inhaled fluticasone propionate can inhibit further progression of established structural airway changes.
METHODS: Sensitized Brown Norway rats were exposed to aerosolized ovalbumin (1%) from day 14 to 42. From day 28 to 42, animals were treated with inhaled fluticasone or placebo 30 min before each allergen challenge. One control group was exposed to PBS from day 28 to 42, a second control group throughout the whole experiment.
RESULTS: Exposure to ovalbumin during 2 weeks induced structural airway changes, including epithelial cell proliferation, increase in airway wall area and fibronectin deposition. Goblet cell number was increased, although not significantly compared with PBS. Continuing allergen exposure for 2 weeks further enhanced each of these features. In addition, the amount of collagen in the airway wall was enhanced by 4 weeks allergen exposure compared with PBS-exposed animals. These additional increases were inhibited by treatment with fluticasone during the last 2 weeks.
CONCLUSION: The progression of established allergen-induced structural airway changes in sensitized rats can be inhibited by treatment with fluticasone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047439     DOI: 10.1046/j.1365-2222.2002.01394.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

Review 1.  Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma.

Authors:  Raymond B Penn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-16       Impact factor: 3.000

2.  Genetic Deletion of β-Arrestin-2 and the Mitigation of Established Airway Hyperresponsiveness in a Murine Asthma Model.

Authors:  Minyong Chen; Akhil Hegde; Yeon Ho Choi; Barbara S Theriot; Richard T Premont; Wei Chen; Julia K L Walker
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

3.  Targeted HAS2 Expression Lessens Airway Responsiveness in Chronic Murine Allergic Airway Disease.

Authors:  Julia K L Walker; Barbara S Theriot; Michael Ghio; Carol S Trempus; Jordan E Wong; Victoria L McQuade; Jiurong Liang; Dianhua Jiang; Paul W Noble; Stavros Garantziotis; Monica Kraft; Jennifer L Ingram
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

4.  Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease.

Authors:  John F Alcorn; Lisa M Rinaldi; Elizabeth F Jaffe; Mirjam van Loon; Jason H T Bates; Yvonne M W Janssen-Heininger; Charles G Irvin
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

Review 5.  Factors controlling airway smooth muscle proliferation in asthma.

Authors:  Alastair G Stewart; John V Bonacci; Lilly Quan
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

6.  Glucocorticoid inhibition of interleukin-4 (IL-4) and interleukin-13 (IL-13) induced up-regulation of arginase in rat airway fibroblasts.

Authors:  Dirk Lindemann; Kurt Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

7.  Assessment of peripheral airway function following chronic allergen challenge in a sheep model of asthma.

Authors:  Joanne Van der Velden; Donna Barker; Garry Barcham; Emmanuel Koumoundouros; Kenneth Snibson
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

8.  Prolonged ozone exposure in an allergic airway disease model: adaptation of airway responsiveness and airway remodeling.

Authors:  An-Soo Jang; Inseon-S Choi; Jae-Hyuk Lee; Chang-Soo Park; Choon-Sik Park
Journal:  Respir Res       Date:  2006-02-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.